Halia Therapeutics Welcomes Paul Jones as Chief Strategy Officer to Enhance Global Genomics Leadership

Halia Therapeutics Strengthens Leadership with Strategic Appointment

Halia Therapeutics, recognized as The Genetic Resilience Company and a clinical-stage biopharmaceutical entity, has recently announced a significant leadership move by appointing Paul Jones as its Chief Strategy Officer and General Manager of International Markets. This newly established position emphasizes the company's enduring commitment to advancing resilience-based therapeutic development and strengthening collaboration with the Department of Health in Abu Dhabi.

In his new role, Jones will spearhead initiatives to accelerate the GENMOR-AI platform. This proprietary system employs artificial intelligence to pinpoint genetic modifiers related to various diseases. With his appointment, Halia is set to enhance its collaboration with the Department of Health – Abu Dhabi, utilizing the Emirati Genome dataset to explore genetic resilience factors that bolster individuals against diseases.

David Bearss, Ph.D., the CEO of Halia Therapeutics, expressed, “We are thrilled to welcome Paul to Halia. His extensive background in large-scale genomic projects sets him apart and perfectly complements our team.” Jones has a rich experience that spans over three decades in the life sciences sector, with a specialized focus on genomics, digital health transformation, and precision medicine, among other disciplines.

Prior to joining Halia, Jones served as the CEO of the Omics Centre of Excellence at M42, a health tech giant based in Abu Dhabi. He played an instrumental role in the Emirati Genome Program—one of the most significant national genomics initiatives globally—while fostering collaborations with government entities, academic institutions, and industry stakeholders.

His previous experience includes leadership roles at renowned organizations including Illumina and Genomics England, where he contributed significantly to the landmark 100,000 Genomes Project. Additionally, Jones has held consultative positions at major corporations such as Cisco and Novartis, providing insight into the integration of genomics within healthcare systems worldwide.

Jones's expertise is poised to enhance Halia's APOE4 program focusing on Alzheimer's disease, which investigates individuals with the highest-risk genetic variant yet who do not manifest the disease. The application of GENMOR-AI to extensive genomic datasets aims to unveil resilience mechanisms that can pave the way for novel therapies addressing neurodegeneration, metabolic disorders, and even cardiovascular diseases.

Expressing his enthusiasm for this new chapter, Jones stated, “The focus on genetic resilience over mere disease risk signifies a breakthrough in precision medicine. Halia's integration of advanced AI with strategic global partnerships positions the company to revolutionize drug discovery and improve patient health outcomes.”

About Halia Therapeutics

Halia Therapeutics is a pioneering clinical-stage biopharmaceutical firm dedicated to addressing the root causes of inflammation through discovery and innovation. By leveraging genetic insights alongside AI-enabled approaches, Halia is developing a robust pipeline of therapeutics targeting inflammatory pathways associated with a range of conditions from neurodegenerative diseases to hematologic malignancies. The company's mission is deeply rooted in creating data-driven treatments that not only extend life expectancy but also significantly enhance the quality of life for patients.

Headquartered in Lehi, Utah, Halia is rapidly forming global alliances in clinical research, drug discovery, and personalized healthcare. To learn more about Halia Therapeutics and its pioneering work, please visit www.haliatx.com or connect on LinkedIn and Twitter (@HaliaTx).